Loading…
Rubicon Research
Accepting projectsDriven by Innovation through focused R&D
Capabilities & focus
Process-development services
Formulation developmentProduct development and commercialisationRegulatory filings
Technology platforms
Proprietary drug delivery technologies including RubiReten (a gastro-retentive system for drugs with poor solubility and a limited absorption window) and RubiSRL (sustained-release liquids combining ion exchange and membrane diffusion controlled release)plus stated experience with barrier membranematrix and osmotic systems. Dosage forms manufactured: oral solid dose (tabletscapsulesdispersible tabletspowders)oral liquids (syrupssuspensionssolutions)and unit-dosebi-dose and multi-dose nasal sprays; the wider marketed portfolio also includes ophthalmic drops and intrathecal injections.
Public
Ownership
1999
Founded
Live record · illustrative seed data · scores deterministic, rules-based — not AI. Not a regulatory determination or endorsement.